Draft monograph: Gonadorelin — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. The absence of a rare harm in the trial set is presented as reassurance — arising from DRAFT-GONADORELIN-/002. Wherever the monograph reports that an event was not observed, it now states the total exposure and the frequency the contributing trials could have detected, so that the absence is read as the limit of the evidence rather than as a finding.
2. The monograph does not tell a reader that a stated mass may be substantially counter-ion and water — arising from DRAFT-GONADORELIN-/001. The monograph now states, at the point where vial contents are first mentioned, that a mass figure is uninterpretable unless it states whether it is peptide content or total solids, and cross-references the content standard in the analytical series.
3. The recorded evidence gaps omit outcomes a reader would consider material — arising from DRAFT-GONADORELIN-/005. The evidence-gap section is now derived from the anchor and decision-relevant outcomes for the indication, and any such outcome measured by no contributing trial is recorded as not measured rather than omitted.
4. Every contributing trial shares one sponsor and the monograph does not say so — arising from DRAFT-GONADORELIN-/006. Sponsor concentration is now stated with the certainty rating, and the monograph records how many independent sponsors contributed evidence to each assessed outcome.
5. The monograph should reproduce the approved labelling rather than paraphrase it — arising from DRAFT-GONADORELIN-/007. The approved indication and contraindications are now reproduced verbatim from the named authorisation with its version and date, and the posology section reports the labelled schedule and the schedules studied side by side, with the source of each stated.
6. The pharmacokinetic section does not connect half-life to the dosing schedule — arising from DRAFT-GONADORELIN-/008. The pharmacokinetic section now states approximate time to steady state alongside the half-life and dosing interval, with the assumption of first-order elimination stated, and records where the assumption is not supported for this compound.
7. Effect estimates are given without naming the comparator — arising from DRAFT-GONADORELIN-/004. The comparator is now stated in every outcome row, and estimates against different comparators are reported in separate tables with the comparator named in the table caption.
8. Absence of evidence is presented in a form a reader will take as negative evidence — arising from DRAFT-GONADORELIN-/003. A standing formulation has been adopted and is applied wherever an evidence gap is recorded, distinguishing an outcome assessed and not demonstrated from an outcome not assessed. The formulation is identical at every occurrence so that it can be recognised at…

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.